Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Nuvalent Yönetim

Yönetim kriter kontrolleri 3/4

Nuvalent's CEO'su Jim Porter, Feb2020 tarihinde atandı, in görev süresi 4.67 yıldır. in toplam yıllık tazminatı $ 9.38M olup, şirket hissesi ve opsiyonları dahil olmak üzere 6.4% maaş ve 93.6% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.11% ine doğrudan sahiptir ve bu hisseler $ 7.70M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.3 yıl ve 3.8 yıldır.

Anahtar bilgiler

Jim Porter

İcra Kurulu Başkanı

US$9.4m

Toplam tazminat

CEO maaş yüzdesi	6.4%
CEO görev süresi	4.7yrs
CEO sahipliği	0.1%
Yönetim ortalama görev süresi	3.3yrs
Yönetim Kurulu ortalama görev süresi	3.8yrs

Son yönetim güncellemeleri

Recent updates

Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Apr 22

Nuvalent: Pivotal NSCLC Programs Progressing With Additional Data In 2024

Feb 26

Is Nuvalent, Inc. (NASDAQ:NUVL) Trading At A 36% Discount?

Jan 07

Companies Like Nuvalent (NASDAQ:NUVL) Can Afford To Invest In Growth

Sep 23

Here's Why We're Not At All Concerned With Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Jun 10

We're Interested To See How Nuvalent (NASDAQ:NUVL) Uses Its Cash Hoard To Grow

Feb 24

Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Sep 13

Nuvalent GAAP EPS of -$0.38 beats by $0.03

Aug 10

Here's Why We're Not At All Concerned With Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

May 28

We're Hopeful That Nuvalent (NASDAQ:NUVL) Will Use Its Cash Wisely

Oct 29

CEO Tazminat Analizi

Jim Porter'un ücretlendirmesi Nuvalent'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$174m
Mar 31 2024	n/a	n/a	-US$146m
Dec 31 2023	US$9m	US$603k	-US$126m
Sep 30 2023	n/a	n/a	-US$114m
Jun 30 2023	n/a	n/a	-US$100m
Mar 31 2023	n/a	n/a	-US$89m
Dec 31 2022	US$5m	US$580k	-US$82m
Sep 30 2022	n/a	n/a	-US$73m
Jun 30 2022	n/a	n/a	-US$66m
Mar 31 2022	n/a	n/a	-US$57m
Dec 31 2021	US$5m	US$424k	-US$46m
Sep 30 2021	n/a	n/a	-US$36m
Jun 30 2021	n/a	n/a	-US$28m
Mar 31 2021	n/a	n/a	-US$27m
Dec 31 2020	US$759k	US$335k	-US$15m

Tazminat ve Piyasa: Jim 'ın toplam tazminatı ($USD 9.38M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 8.11M ).

Tazminat ve Kazançlar: Jim şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Jim Porter (48 yo)

4.7yrs

Görev süresi

US$9,376,872

Tazminat

Dr. James R. Porter, also known as Jim, Ph.D. has been Chief Executive Officer and President of Nuvalent, Inc. since February 1, 2020 and has been Director since February 2020. He joined Nuvalent during co...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
James Porter	CEO, President & Director	4.7yrs	US$9.38m	0.11% $ 7.9m
Matthew Shair	Founder	7.7yrs	US$688.18k	2.34% $ 173.3m
Alexandra Balcom	CFO & Treasurer	3.8yrs	US$3.54m	0.047% $ 3.5m
Christopher Turner	Chief Medical Officer	3.6yrs	US$3.60m	0.021% $ 1.5m
Benjamin Lane	Senior Vice President of Technical Operations	2.3yrs	Veri yok	Veri yok
Henry Pelish	Chief Scientific Officer	less than a year	Veri yok	Veri yok
Deborah Miller	Chief Legal Officer & Secretary	3.3yrs	US$1.69m	0.047% $ 3.5m
Matthew Metivier	Senior Vice President of Human Resources	2.6yrs	Veri yok	Veri yok
Darlene Noci	Chief Development Officer	3.8yrs	Veri yok	0.047% $ 3.5m
John Soglia	Senior Vice President of Translational Development	1.7yrs	Veri yok	Veri yok
Perrin Wilson	Senior Vice President of Business Development & Strategy	1.1yrs	Veri yok	Veri yok

3.3yrs

Ortalama Görev Süresi

48yo

Ortalama Yaş

Deneyimli Yönetim: NUVL 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
James Porter	CEO, President & Director	4.7yrs	US$9.38m	0.11% $ 7.9m
Matthew Shair	Founder	7.7yrs	US$688.18k	2.34% $ 173.3m
Sapna Srivastava	Independent Non-Executive Director	3.3yrs	US$503.18k	0% $ 0
Anna Protopapas	Independent Chairman	2.6yrs	US$523.18k	0% $ 0
Pasi Antero Janne	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
D. Gilliland	Independent Non-Executive Director	3.8yrs	US$495.68k	0% $ 0
Michael Meyers	Member of Scientific Advisory Board & Independent Director	2yrs	US$494.36k	0% $ 0
Cameron Wheeler	Independent Non-Executive Director	7.7yrs	US$499.45k	Veri yok
Joseph Pearlberg	Independent Non-Executive Director	3.8yrs	US$494.00k	Veri yok
Emily Conley	Independent Director	2.7yrs	US$495.90k	0.000010% $ 740.3
D. Camidge	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Aaron Hata	Member of Scientific Advisory Board	no data	Veri yok	Veri yok

3.8yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: NUVL 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.8 yıldır).

Nuvalent Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

CFO & Treasurer notifies of intention to sell stock

CFO & Treasurer exercised options and sold US$564k worth of stock

CFO & Treasurer exercised options and sold US$517k worth of stock

Nuvalent, Inc. Announces Promotion of Henry Pelish to Chief Scientific Officer

CFO & Treasurer notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Recent updates

CFO & Treasurer notifies of intention to sell stock

Nuvalent: Promising Data Keeps Validating Pipeline And Platform

Nuvalent, Inc. has completed a Follow-on Equity Offering in the amount of $500 million.

Nuvalent: Likely Approvals Coming Up Do Not Justify This Valuation

Nuvalent, Inc. has completed a Follow-on Equity Offering in the amount of $500 million.

Price target increased by 8.1% to US$111

Nuvalent, Inc. has filed a Follow-on Equity Offering in the amount of $350 million.

Nuvalent, Inc. Announces Publication in Cancer Discovery Detailing Design and Characterization of Alk-Selective Inhibitor Nvl-655

CFO & Treasurer exercised options and sold US$564k worth of stock

New major risk - Revenue and earnings growth

Nuvalent (NASDAQ:NUVL) Is In A Strong Position To Grow Its Business

CFO & Treasurer exercised options and sold US$517k worth of stock

Nuvalent, Inc. Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective Inhibitor

Nuvalent, Inc. Announces Promotion of Henry Pelish to Chief Scientific Officer

CFO & Treasurer notifies of intention to sell stock

Nuvalent: Making Precise Progress In Its Oncology Pipeline

Independent Director notifies of intention to sell stock

Nuvalent: NVL-655 Could Bring Blockbuster Potential

Chief Legal Officer & Secretary exercised options and sold US$528k worth of stock

Nuvalent, Inc. Receives U.S. FDA Breakthrough Therapy Designation for NVL-655

Nuvalent, Inc., Annual General Meeting, Jun 12, 2024

Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Price target increased by 10% to US$102

Independent Director notifies of intention to sell stock

Price target increased by 8.6% to US$92.13

Nuvalent: Pivotal NSCLC Programs Progressing With Additional Data In 2024

Price target increased by 7.4% to US$84.83

Nuvalent, Inc. Initiates the Phase 2 Portion of Alkove-1 Clinical Trial for Patients with Alk-Positive Nsclc and Other Solid Tumors

Is Nuvalent, Inc. (NASDAQ:NUVL) Trading At A 36% Discount?

Chief Development Officer notifies of intention to sell stock

Founder notifies of intention to sell stock

Chief Development Officer notifies of intention to sell stock

New minor risk - Share price stability

Price target increased by 11% to US$59.14

Companies Like Nuvalent (NASDAQ:NUVL) Can Afford To Invest In Growth

Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium

Nuvalent Initiates the Phase 2 Portion of ARROS-1 Clinical Trial for Patients with Ros1-Positive NSCLC and Other Solid Tumors

New major risk - Revenue and earnings growth

Price target increased by 8.7% to US$50.83

Chief Legal Officer & Secretary notifies of intention to sell stock

Price target increased by 8.7% to US$50.80

Chief Legal Officer & Secretary notifies of intention to sell stock

Chief Development Officer notifies of intention to sell stock

Here's Why We're Not At All Concerned With Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Chief Development Officer exercised options and sold US$125k worth of stock

Price target increased by 10% to US$46.75

Chief Development Officer exercised options and sold US$113k worth of stock

Chief Development Officer exercised options and sold US$77k worth of stock

Chief Development Officer exercised options and sold US$86k worth of stock

We're Interested To See How Nuvalent (NASDAQ:NUVL) Uses Its Cash Hoard To Grow

Chief Legal Officer & Secretary notifies of intention to sell stock

Chief Development Officer exercised options and sold US$85k worth of stock

Chief Legal Officer & Secretary exercised options and sold US$51k worth of stock

Chief Development Officer exercised options and sold US$121k worth of stock

Nuvalent Inc. Announces Publication in Cancer Discovery Detailing Design and Characterization of ROS1-selective inhibitor NVL-520

Chief Development Officer exercised options and sold US$130k worth of stock

Price target increased to US$43.67

High number of new directors

Chief Legal Officer & Secretary exercised options and sold US$287k worth of stock

Nuvalent, Inc. Reports Preliminary Phase 1 Clinical Data from ARROS-1 Trial that Support Best-In-Class Potential of NVL-520 for Patients withROS1-Positive NSCLC

Chief Development Officer exercised options and sold US$85k worth of stock

Nuvalent, Inc. Currently Enrolling Patients in the Phase 1 Portion of Its Arros-1 Study, A Phase 1/2 Clinical Trial

Chief Development Officer exercised options and sold US$72k worth of stock

Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Nuvalent, Inc. Present Preliminary Phase 1 Data from ARROS-1 Clinical Trial of NVL-520 at 34th EORTC-NCI-AACR Symposium and Announces Pipeline Updates

Nuvalent GAAP EPS of -$0.38 beats by $0.03

Nuvalent, Inc. Presents New Preclinical Data Supporting Potential Best-In-Class Profile for ALK-Selective Inhibitor NV-655 At IASLC 2022 World Conference on Lung Cancer Annual Meeting

Nuvalent, Inc. Announces Leadership Promotions

Insider exercised options and sold US$278k worth of stock